Neovasc has announced today its notable presentations at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA). On 31 October, Anson Cheung (St Paul’s hospital, Vancouver, Canada) presented an update on the ongoing Tiara programme, discussing the clinical data to date for the 19 patients treated with the Neovasc Tiara transcatheter mitral valve implantation (TMVI) valve. The 30-day survival rate for these 19 patients is 84%. Overall, the data presented was very encouraging, in this very sick cohort of patients treated with Tiara.
Cheung elaborated that enrolment continues in the TIARA-I early feasibility trial and in other compassionate use programmes. The TIARA-I trial is assessing the safety and performance of the Tiara mitral valve system and the implantation procedure in high-risk patients suffering from severe mitral regurgitation.
Also, Florian Deuschl (Hamburg, Germany) gave a presentation entitled “Echocardiographic guiding of a novel mitral valve Replacement”, which reviewed his positive experience from the Tiara implantation cases performed by the team in Hamburg.
Additionally, Gregg Stone (USA) discussed the use of Neovasc’s Reducer for the treatment of refractory angina (despite optimal medical therapy). He reviewed the results of the COSIRA randomised study which was published in The New England Journal of Medicine last year, and also outlined the design of the COSIRA II, pivotal US trial, (which will include 380 patients and will be a multicentre prospective, randomized, double-blind, sham-controlled trial).
In addition, during the conference there were two posters presented from Italy, describing the positive effect of the Neovasc Reducer.